VTVT

vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in High Point, North Carolina. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and focuses on developing orally administered treatments primarily for diabetes and other metabolic disorders. Since its initial public offering in July 2015, vTv has been advancing a pipeline of small molecule therapeutics through various stages of clinical development, with particular emphasis on innovative approaches to treating type 1 diabetes and inflammatory conditions.